Seoul Economic Daily EnglishQwen · 实盘不做把握 6/10不做原因:已被定价
北京时间·🕒 发布 10:02:50(首尔 11:02)·⟳ 抓取 10:12:35 +9m45s·⚡ 决策 09-14 17:13:43 +7h01m·43.5 天前
爱茉莉太平洋在2026 Investor Day提出2035年集团营收15万亿韩元目标，以皮肤科学美妆与护发为全球增长引擎
事件本体是9月11日已发生的投资者日长期战略（FY2035/FY2030/FY2027目标），9月14日只是媒体回顾稿；同日韩股盘中该股已放量+3.91%并冲高回落，说明该催化已在唯一有效窗口内被实时定价。剩余可执行时点是9月15日开盘追高，而催化是9年跨度的软指引、无金额型近端增量、市值约10万亿韩元，正期望不足；二阶映射（韩股ODM、A股化妆品）无点名供应/客户关系，无法坐实因果敞口，故整体AVOID。
📄 原文Seoul Economic Daily English↗ 原文
Amorepacific Targets 15 Trillion Won in Sales by 2035
Amorepacific (090430.KS) will build up its dermatology-focused beauty and hair care businesses as global growth drivers…
不做 爱茉莉太平洋（090430.KS）
长期战略软催化且事件已发生3天：9月11日投资者日给出FY2035集团营收15万亿韩元、FY2030皮肤科学美妆与护发各1万亿韩元、FY2027收入+10%/营业利润率>11%，均为多年期愿景，无订单、回购或近端盈利上修等可核验金额增量；相对约10.06万亿韩元市值，单窗口materiality极低。价格上，9月14日韩股盘中该股已放量+3.91%（开143000、高148700、收146000、量比1.44x）并自高点回落，催化已在唯一有效窗口内被实时定价；研判时点韩股收…
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
结论摘要
投资者日给出的是2035年15万亿韩元营收等长期愿景与FY2027『收入+10%/营业利润率>11%』软指引，无订单、回购或近端盈利上修等可核验增量；股价已在9月14日韩股盘中放量+3.9%并自高点回落，唯一可执行窗口只剩次日追高，催化已被定价且量级相对10万亿韩元市值过小，故不做。
🔎 新鲜度:最早出现 2026-09-11 · 扩散 medium · price-in 风险 high ↗
消息传播链
- 2026-09-11首发爱茉莉太平洋 2026 Investor Day（首尔龙山总部，公司自述披露）非一手长期战略与FY2027/FY2030/FY2035目标在9月11日投资者日现场首次披露；本轮联网搜索未取回公司IR或交易所原始链接，故该节点仅按正文转述记录，未核验市场反应:090430.KS 当日+1.44%（开135600、高140800、收140500），反应温和
- 事件后第3个交易日的回顾稿，非首发；内容为公司已公开的战略目标复述，无新增金额、订单、指引修正或官方新确认市场反应:090430.KS 当日开143000（+1.8%跳空）、高148700（+5.8%）、收146000（+3.91%），量比1.44x，收盘自日内高点回落约1.8%
- 2026-09-14 18:08 KST市场反应stock_quote（yfinance，日线截至2026-09-14）非一手研判时点韩股已收盘且不可成交，最近收盘146000韩元、市值约10.06万亿韩元、20日累计+7.59%、距52周高-12.86%；下一可执行窗口为9月15日开盘市场反应:当日+3.91%，为近10个交易日最大单日涨幅
关键理由
- 长期战略方向确为正面（海外占比目标>60%、Aestura再进9个市场、IOPE进欧洲），但全部为2030/2035口径，无法在任何交易窗口内转成收入、利润或现金流的已实现增量
- 股价13周轨迹由100升至137、距60日高仅-4.26%、9月14日量比1.44x收+3.91%，属趋势已上、催化当日兑现完毕，次日开盘追高的赔率差
主要风险
- 冲高回落形态（高148700→收146000）叠加2天后FOMC利率决议，若板块情绪转弱，追高腿的回撤风险大于剩余上行空间
- 本轮联网检索未返回可用新闻结果，无法核实9月14日涨幅的真实归因及是否存在同期利空（中国市场、业绩基数、券商下调），该信息缺口本身削弱做多置信度
反向证据
- 做多前查反向 · 来源 web · 影响 none
搜索服务未返回任何相关新闻，无法核实近期是否存在中国市场疲软、业绩不及预期或券商下调等利空；未命中不等于不存在
检索:아모레퍼시픽 2분기 실적 2026 중국 영업이익 부진 증권사 목표주가 - 做多前查反向 · 来源 kb_search · 日期 2026-03-30 · 影响 none
内部KB仅命中2026-03-30公众号旧文《重磅200亿美妆巨头发布核心战略》及茅台、日本地产等无关文档，没有覆盖本次投资者日的研报/纪要，无法用内部数据判断FY2027目标相对一致预期是超预期还是低于预期
检索:爱茉莉太平洋 Amorepacific 2026 Investor Day 长期目标 皮肤科学美妆 Aestura 业绩 原文 ↗ - 做多前查反向 · 来源 kb_search · 日期 2026-08-24 · 影响 supports
案例库显示我们在090430.KS上历史4条决策全部为『不做』（含COSRX英国/欧洲渠道利好、雅诗兰黛业绩、KT×爱茉莉AI研发），从未ENTER，与本次把长期软催化+当日已定价判为不做的处理一致
检索:090430.KS 自家历史决策与同类K-beauty软催化处理记录
先例如何影响了这次决策
对本次决策的影响:先例缺失未改变结论：AVOID由『事件已发生3天+当日已放量定价+软催化无近端金额增量+次日只能追高』独立支撑
方向:无可用先例样本；未能就『韩股大盘消费股投资者日长期目标披露』给出方向/胜率读数
涨幅量级:无高相似、锚干净的先例可校准幅度；本轮未据先例设定tp/sl
形态:无法从先例判断见光死概率；但本标的自身9月14日日线已呈『跳空高开→冲高148700→收146000』的当日冲高回落，属催化兑现后的派发形态
工具执行结果 · 成功 11 · 降级 1 · 失败 0 · 取消 0
- search_processed_events 成功 stock_tools HTTP · 16 ms
{"result": "search_processed_events:agent query=`aestura illiyoon dermatology beauty global expansion | amorepacific 2035 15 trillion won revenue target | amorepacific fiscal 2027 10% revenue growth operating margin 11% | 爱茉莉太平洋 `；结构化索引覆盖完整 72 小时；旧记录兼容扫描近 0.0/72 小时、0 条本臂决策(完整)，返回 0 条候选。未命中只表示这些 agen - stock_quote 降级 stock_tools HTTP · 3,743 ms
{ - kb_search 成功 stock_tools HTTP · 2,607 ms
{ - fetch_decision_experience 成功 stock_tools HTTP · 39 ms
{ - web_search 成功 Bing RSS · 255 ms
Bing RSS 搜索结果（原始查询:아모레퍼시픽 인베스터데이 2026 매출 15조 목표 주가 상승） - web_search 成功 Bing RSS · 329 ms
Bing RSS 搜索结果（原始查询:Amorepacific stock September 14 2026 investor day shares rise analyst） - web_search 成功 Bing RSS · 623 ms
Bing RSS 搜索结果（原始查询:아모레퍼시픽 2분기 실적 2026 중국 영업이익 부진 증권사 목표주가） - web_search 成功 Bing RSS · 297 ms
Bing RSS 搜索结果（原始查询:Korean company investor day long-term revenue target announcement stock reaction muted 코스맥스 한국콜마 아모레） - web_search 成功 Bing RSS · 262 ms
Bing RSS 搜索结果（原始查询:"Amorepacific" investor day 2035 15 trillion won dermatology hair care targets） - web_search 成功 Bing RSS · 247 ms
Bing RSS 搜索结果（原始查询:K-beauty stocks rally Amorepacific Cosmax Korea Kolmar September 2026 shares jump） - search_case_library 成功 stock_tools HTTP · 42 ms
{"result": "search_case_library「090430.KS」—— 与这些标的相关的自家决策案例(本页 4 条,该标的全历史相关记录共 4 条；ENTER 只按该标的自己的腿统计):\n◆ 090430.KS：相关历史决策 4 条 · 其中该标的 ENTER 0 条(0.0%) · 我们从没在这只票上 ENTER 过\n【对所查标的真 ENTER 过的:0 条 —— 相关案例里没有该标的自己的 ENTER 腿】\n【最近 4 条其它决策(多为「不做」,用来看这票最近在被什么消息刷屏)】\n• 2026-08-24 UTC 不做 · 事件:COSRX宣布以Patron身份加 - web_search 成功 Bing RSS · 255 ms
Bing RSS 搜索结果（原始查询:Amorepacific 090430 second quarter 2026 earnings operating profit China US revenue Aestura growth）
原文全文
展开原文 · 2,227 字
Amorepacific (090430.KS) will build up its dermatology-focused beauty and hair care businesses as global growth drivers as it targets 15 trillion won ($10.8 billion) in group revenue by 2035.
The company said on Sept. 14 that it unveiled global growth strategies for its dermatology beauty and hair care brands at its 2026 Investor Day, held on Sept. 11 at its headquarters in Yongsan, Seoul. In dermatology beauty, the company will expand overseas around its Aestura and Illiyoon brands, aiming for 1 trillion won in revenue from dermatology beauty brands in fiscal 2030, which runs from July 2029 to June 2030.
Aestura, which has entered 36 countries over the past three years, will add nine more markets by the first half of next year to accelerate its global expansion. Illiyoon will develop its Ato Cream as a flagship global product, while IOPE will enter the European market in the first half of next year following its launch at Sephora in the U.S., with a goal of becoming a brand generating 500 billion won in revenue by 2035.
The company is also stepping up its hair care push. Building on a multi-brand portfolio that includes Ryo and Mise en Scene, it aims for 1 trillion won in revenue by fiscal 2030. To lift the share of overseas sales above 60%, it will expand in major markets including the U.S., China, Japan and Brazil, focusing on premium hair care and scalp care while developing flagship global products for each brand.
Amorepacific will also strengthen its digital capabilities. It plans to broaden consumer touchpoints on major digital channels such as social media and e-commerce, and to refine its marketing using consumer data and insights by market and channel. Through these efforts, the company aims for 10% revenue growth and an operating margin of more than 11% in fiscal 2027, the year running from July 2026 to June 2027.
"We will accelerate the growth of our existing flagship brands and develop dermatology beauty, clinical skin care and hair care into new global growth pillars," Amorepacific CEO Kim Seung-hwan said. "We will respond nimbly to changes in customers and markets driven by social media, e-commerce and artificial intelligence to create sustainable growth in global markets."
The company said on Sept. 14 that it unveiled global growth strategies for its dermatology beauty and hair care brands at its 2026 Investor Day, held on Sept. 11 at its headquarters in Yongsan, Seoul. In dermatology beauty, the company will expand overseas around its Aestura and Illiyoon brands, aiming for 1 trillion won in revenue from dermatology beauty brands in fiscal 2030, which runs from July 2029 to June 2030.
Aestura, which has entered 36 countries over the past three years, will add nine more markets by the first half of next year to accelerate its global expansion. Illiyoon will develop its Ato Cream as a flagship global product, while IOPE will enter the European market in the first half of next year following its launch at Sephora in the U.S., with a goal of becoming a brand generating 500 billion won in revenue by 2035.
The company is also stepping up its hair care push. Building on a multi-brand portfolio that includes Ryo and Mise en Scene, it aims for 1 trillion won in revenue by fiscal 2030. To lift the share of overseas sales above 60%, it will expand in major markets including the U.S., China, Japan and Brazil, focusing on premium hair care and scalp care while developing flagship global products for each brand.
Amorepacific will also strengthen its digital capabilities. It plans to broaden consumer touchpoints on major digital channels such as social media and e-commerce, and to refine its marketing using consumer data and insights by market and channel. Through these efforts, the company aims for 10% revenue growth and an operating margin of more than 11% in fiscal 2027, the year running from July 2026 to June 2027.
"We will accelerate the growth of our existing flagship brands and develop dermatology beauty, clinical skin care and hair care into new global growth pillars," Amorepacific CEO Kim Seung-hwan said. "We will respond nimbly to changes in customers and markets driven by social media, e-commerce and artificial intelligence to create sustainable growth in global markets."
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。